logo
Bill Gates Will Close Gates Foundation by 2045, Give Fortune to Global Health

Bill Gates Will Close Gates Foundation by 2045, Give Fortune to Global Health

Yahoo08-05-2025

Bill Gates at The 11th Breakthrough Prize Ceremony held at Barker Hanger on April 5, 2025 in Santa Monica, Calif. Credit - Gilbert Flores/Variety—Getty Images
So far, 2025 has been a terrible year for global health. The Trump Administration is slashing funding to a number of international programs; closing down USAID, the government's major aid development arm; and withdrawing U.S. membership from the World Health Organization.
But a glimmer of hope arrived on May 8, when Bill Gates, chair of the Gates Foundation, announced that he will be infusing the struggling field with most of his fortune—$200 billion, which he built after creating Microsoft—to be spent by 2045. He also plans to close down the foundation at that time.
Since Gates and his former wife, Melinda French Gates, created the foundation 25 years ago, the organization has contributed more than $100 billion to global causes, primarily in health. The Gates Foundation helped to create two important international health organizations: GAVI, which provides the world's children with lifesaving vaccines, and the Global Fund, which focuses on distributing treatments for HIV, TB, and malaria.
Gates' just-announced timeline represents an acceleration of foundation's timetable. When it was created, the board agreed to sunset the organization about 20 years after the Gates' deaths.
Gates, who turns 70 this year, spoke with TIME about why he decided to speed up his plans.
Over the last two years, I've been talking with [Gates Foundation CEO] Mark Suzman and the foundation board about this. And we decided to double down to get some infectious diseases either dramatically reduced or eradicated, which is exciting.
It is ironic that the announcement ended up being at a time where the funding for global health is in incredible crisis because of a lot of cuts being made and some that are being discussed. This was not a response to that. But perhaps my commitment to give all of it away will remind people how important and how effective these dollars are, and the basic value of reducing childhood deaths. So it was late last year that I really put it to the board and talked about doubling down.
In the two discussions I had with President Trump since he was elected—on Dec 27. and Feb. 5—he was quite supportive of our work in HIV and polio. It's Congress who will set the budget going forward, and historically, PEPFAR, which was created by President Bush [to provide HIV treatments] and GAVI had bipartisan support, and less than 1% of the U.S. budget goes to these things. Some of that funding has been cut off right now, in fact in a pretty abrupt way. We need to get Congress to weigh in.
Read More: The 100 Most Influential People in Health
I am hopeful that we can get a lot of that funding restored, but we do have challenges in a lot of rich countries where budgets are very tight, and they are under pressure to increase defense budgets. Over the next four years, we are likely to see an increase in childhood deaths for the first time since the turn of the century, and I am very dedicated to changing things to help us get back to making progress. We need rich world governments to restore some of this funding; we need more engagement by philanthropies to help out. And incredible innovations mean whatever money we have can be used even more effectively. Over [the next] 20-year period, I am actually quite optimistic, although we are in an awful emergency right now.
The WHO is a key partner for us. In fact [WHO director general] Tedros [Ghebreyesus] was in Singapore with me on Tuesday, and we were talking about the reorganization he is going through and decisions he has made. WHO plays a big role in polio and most of the things we do in global health. Strangely, now that U.S. cut so much, the Gates Foundation is now the largest single donor to WHO. I don't think in the long run that's the way it should be. A big part of that is the work we do in polio, but we fund a dozen things at WHO.
But I think eventually the U.S. will state whatever it wants to see changed and resume as a member, because in so many areas, WHO is critical, including whenever we have a potential pandemic. You know, we funded a lot of the improvement pandemic preparedness of the WHO based on lessons that came out of the COVID vaccine effort. I don't think the U.S. will go back in right away, but we'll be somebody to help broker a dialogue that eventually gets the U.S. back there, which think is valuable to the world and U.S.
I would have guessed because the U.S. does have problems with the deficit, we might see a 15%-20% cut. I would have said, okay, we need to make sure we minimize the impact that has. I think it's ideal at this point that we get back to that.
There are some proposals to Congress from the executive branch which would represent an almost 80% cut. That would be tragic. We are going to see deaths from children go up, and they have been going down at a record rate since 2000, from 10 million to under 5 million. We are going to see it go the wrong way, and that means millions of extra deaths. Some of the cut-offs have been quite abrupt.
Read More: Medicaid Expansions Saved Tens of Thousands of Lives, Study Finds
We will get a real gauge of this global health emergency in June in Brussels, for the five-year replenishment of GAVI: that entity we started in 2000 together with rich world governments to buy vaccines for the world's poorest children. The metric will be—can we raise as much as we raised five years ago, or will we be substantially below that? I have to tell you, right now, it looks pretty grim. Including getting the U.S. to buy these very inexpensive vaccines. These are $1 vaccines, and the majority of the reason we had reductions in deaths from around 10 million to five million is because of vaccines. To not be able to buy $1 vaccines when we are talking [about something] that is well under 1% of the U.S. budget, I think that's tragic. We will try to make the case, try keep the U.S. in HIV medicines, where they have been very generous, starting with President Bush. The Global Fund replenishment will come in the fall, and right now, it all looks like it could be a disaster.
If you look at the breakdown of the foundation spending, which is just over $100 billion over the last 25 years, by far the biggest is in global health, with 35% creating new, low-cost tools and 35% helping to get those tools delivered.
Next up is education, which is about 15%. That's always been something where because I got such a great education here in the U.S., I felt like we should try to make that available to every student. We have done a lot with charter schools, curriculums, and scholarships. Now, we are using AI to improve curricula. We are able to get graduation levels up.
Agriculture is 8% of what we have done. The opportunity to make seeds more productive, and crops more nutritious either by improving seeds or doing food fortification by adding some micronutrients in later—that's super important work. Particularly in Africa where with population growth and climate change, the only way to help the poorest there—the majority of whom are farmers—is by improving their seeds and access to fertilizer.
One of the most amazing programs we've done is taking chickens in Africa and used cross-breeding with highly productive chickens from Europe and the U.S. to get a lot more eggs. Now we have over 200 million chickens that have been delivered to women in Africa that both help nutritionally, and help them economically. It's a very exciting area. The agriculture work has as high impact as our health work.
The progress in health is way beyond what I would have expected. Tens of millions of lives have been saved because of our work and through our partnerships—over 100 million lives. It's not just us. There has been a movement, and we have been a central part of that.
In areas like education, we have done great things—graduation rates have gone up but not nearly as miraculous. I slightly expected us have more impact in education and I had no idea we we'd be able to have such incredible results in our health work. So we're learning all the time. We've got a pipeline of innovation that is far, far stronger than ever before. And we have AI that's going to supercharge that—both the discovery piece and the delivery piece. So I have pretty high expectations for the next 20 years, despite the funding emergency that we're in .
Contact us at letters@time.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. Bombarded Bill Nye with Autism Texts, TV Scientist Says
RFK Jr. Bombarded Bill Nye with Autism Texts, TV Scientist Says

Newsweek

timean hour ago

  • Newsweek

RFK Jr. Bombarded Bill Nye with Autism Texts, TV Scientist Says

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. TV scientist Bill Nye said he cut Robert F. Kennedy Jr. off after the now-health secretary bombarded him with text messages about autism. The host of Bill Nye the Science Guy, whose show has educated millions of viewers about science, spoke about Kennedy in a new interview with Men's Health. Newsweek has contacted the United States Department of Health and Human Services, via email, for a response. Why It Matters Kennedy has long faced backlash for some of his positions on health and medicine, especially vaccines. During his Senate confirmation in January, Kennedy insisted that he was not anti-vaccine, that he believes vaccines "play a critical role in healthcare." Critics say Kennedy's agenda undermines the scientific process and risks eroding decades of public trust in vaccines, while others argue that his new approach is what Americans voted for. (R) U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. attends President Donald Trump's address to a joint session of Congress at the U.S. Capitol on March 04, 2025 in Washington, D.C. (L)... (R) U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. attends President Donald Trump's address to a joint session of Congress at the U.S. Capitol on March 04, 2025 in Washington, D.C. (L) Bill Nye attends the arrivals of Sierra Club's 2025 Trail Blazers Ball at the Skirball Cultural Center in Los Angeles, CA on April 2, 2025 More Win McNamee//Sipa via AP Images What To Know Nye, who met Kennedy before he became health secretary, through their mutual actor friend Ed Begley Jr., showed what Men's Health reporter Chantel Anderson described as "miles and miles of texts" from Kennedy with "few interruptions, screen after screen." "Just no self-awareness," Nye said. "And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection." Nye said he replied to Kennedy, "Okay, I'll read your book. I think you've confused causation with correlation. Your friend, Bill." But, when Kennedy responded with "more miles of texts," Nye told him: "Okay, no more texts." "And he started again," Nye said, "so I cut him off." He added that Kennedy doesn't have "good judgement" and is "not suited" to be health secretary. Nye went on to speak about the measles outbreak in Texas, where 744 cases have been confirmed since late January, according to the Texas Department of State Health Services. Kennedy has faced criticism from both anti-vax activists and advocates of vaccines. In March, he sparked anger from anti-vax activists when he called on parents to "consult with their healthcare providers to understand their options to get the MMR vaccine," with one saying he is "no different than Fauci." But he has also faced backlash from those in favor of vaccines for some of his comments, including when he told Fox News: "When you and I were kids, everybody got measles, and measles gave you ... lifetime protection against measles infection. The vaccine doesn't do that. The vaccine is effective for some people for life, but for many people, it wanes." Director of the Vaccine Education Center at Children's Hospital of Philadelphia, Dr. Paul Offit, told HealthDay that this could not be true given that measles was declared eliminated in America in 2000. Health and Human Services Secretary Robert F. Kennedy Jr., testifies before a Senate Committee on Appropriations subcommittee hearing to examine proposed budget estimates for fiscal year 2026 for the Department of Health and Human Services,... Health and Human Services Secretary Robert F. Kennedy Jr., testifies before a Senate Committee on Appropriations subcommittee hearing to examine proposed budget estimates for fiscal year 2026 for the Department of Health and Human Services, on Capitol Hill, Tuesday, May 20, 2025, in Washington. More AP What People Are Saying Kennedy said during his confirmation hearing, while arguing that he is not anti-vaccine: "In my advocacy, I've often disturbed the status quo by asking uncomfortable questions. Well, I'm not going to apologize for that – we have massive health problems in this country that we must face honestly." Nye said in his interview with Men's Health: "I went to elementary school with a guy who had polio. You do not want polio! And the reason you don't get polio is because of a vaccine that was discovered that keeps you from getting polio! What is wrong with you, man?" What Happens Next Kennedy is yet to respond to Nye's comments about him. It comes as the health secretary announced eight new experts on a panel that advises the Centers for Disease Control and Prevention.

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

Yahoo

time2 hours ago

  • Yahoo

BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion

BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion. Each share of CureVac, a clinical-stage biotech company, will be exchanged for about $5.46 in BioNTech American depositary shares. Upon the deal's closing, CureVac shareholders are expected to own between 4% and 6% of the German developer of RNA vaccines and immunotherapies. ICE Raids Have Sent Latino Shoppers Into Hiding and Big Brands Are Hurting The Secret to Retaining the Best Employees: Ask Them These Four Questions Here's How Much Money the U.S. Is Earning From Tariffs, in Charts How Home Depot Became Ground Zero in Trump's Deportation Push Supply Chains Become New Battleground in the Global Trade War BioNTech Chief Executive Ugur Sahin said the plan is to bring complementary capabilities between the two companies together to develop transformative cancer treatments. CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech following the close of the transaction. As part of this plan, BioNTech will integrate CureVac's research and manufacturing site in Tübingen, Germany. The deal was unanimously approved by both companies' management and supervisory boards. It is expected to close in 2025. Shares of CureVac surged 29% to $5.25 in premarket trading. Write to Denny Jacob at Pulls Outlook as Sales Fall Bojangles Is Exploring a Sale While the Fried-Chicken Market Is Hot Why Bosses Should Give Feedback in the Morning The Audacious Reboot of America's Nuclear Energy Program Muted May Inflation Defies Tariff Fears Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge

Yahoo

time2 hours ago

  • Yahoo

Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge

Most of UnitedHealth Group's issues should be temporary. The two biggest threats to the healthcare giant are iffy. The price is right to buy UnitedHealth Group stock after its steep decline. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and UnitedHealth Group. The Motley Fool has a disclosure policy. Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store